HilleVax
Founded Year
2021Stage
IPO | IPOTotal Raised
$135MDate of IPO
4/29/2022Market Cap
0.49BStock Price
15.93About HilleVax
HilleVax (NASDAQ: HLVX) is a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates. It was founded in 2021 and is based in Boston, Massachusetts.
Missing: HilleVax's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: HilleVax's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest HilleVax News
Jan 11, 2023
Kevin Tan becomes CFO at Solid Plus: Shook promoted to CMO at Nkarta, and updates from HilleVax, Neurotech, Akero, LifeSci, Dunad and more By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst January 11, 2023 1:50 AM UTC Neuromuscular and cardiac disease company Solid Biosciences Inc. (NASDAQ:SLDB) hired Kevin Tan as CFO. Nkarta Inc. (NASDAQ:NKTX) promoted David Shook to CMO from VP of clinical development. Nkarta is developing NK cell therapies for cancer. ... BCIQ Company Profiles
HilleVax Frequently Asked Questions (FAQ)
When was HilleVax founded?
HilleVax was founded in 2021.
Where is HilleVax's headquarters?
HilleVax's headquarters is located at 75 State St, Boston.
What is HilleVax's latest funding round?
HilleVax's latest funding round is IPO.
How much did HilleVax raise?
HilleVax raised a total of $135M.
Who are the investors of HilleVax?
Investors of HilleVax include Frazier Healthcare Partners, Richard King Mellon Foundation, Greenspring Associates, Sahsen Ventures, Deerfield Management and 12 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.